A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The FDA and the Spanish Ministry of Health have concluded that the risk/benefit ratio is favorable under certain circumstances for clinical studies investigating MDMA-assisted psychotherapy. Both agencies have approved pilot studies in chronic posttraumatic stress disorder (PTSD) patients who have failed to obtain relief from at least one course of conventional treatment. These studies, the only ones in the world into the therapeutic use of MDMA, are being funded by a nonprofit research and educational organization, the Multidisciplinary Association for Psychedelic Studies (MAPS, www.maps.org). A rationale is offered explaining why MAPS chose to focus its limited resources on MDMA, and also on PTSD patients. A Clinical Plan is elaborated for the conduct of the "adequate and well-controlled" trials necessary to evaluate the safety and efficacy of MDMA-assisted psychotherapy for PTSD, with the studies estimated to cost about 5 million dollars and to take about five years. The Clinical Plan has been developed, in part, through analysis of the studies conducted by Pfizer in its successful effort to have Zoloft approved by the FDA for use with PTSD patients, and through review of transcripts of the FDA's Psychopharmacologic Drugs Advisory Committee meeting that recommended approval of Zoloft for PTSD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00148-7 · Cited by 248
Ricaurte, G. A., DeLanney, L. E., Irwin, I., & Langston, J. W. (1988) · Brain Research · doi:10.1016/0006-8993(88)91309-1 · Cited by 245
Camí, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., San, L., & de la Torre, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00010 · Cited by 234 · cited 2×
“A Phase I dose-response safety study has been completed in Spain (Cami et al. 2000; Mas et al. 1999), as well as a study investigating MDMNalcohol in teractions (Hernandez-Lopez et a l .”
BackgroundVollenweider, F. X., Remensberger, S., Hell, D., & Geyer, M. A. (1999) · Psychopharmacology · doi:10.1007/s002130050960 · Cited by 97
Cited by
MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial
Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02565-4 · Cited by 455
Self-citationMolecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Capela, J. P., Carmo, H., Remião, F., Bastos, M. L., Meisel, A., & Carvalho, F. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8064-1 · Cited by 290
Baumann, M. H., Wang, X., & Rothman, R. B. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0322-6 · Cited by 265
Abuse of Amphetamines and Structural Abnormalities in the Brain
Berman, S., O'Neill, J., Fears, S., Bartzokis, G., & London, E. D. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.031 · Cited by 253
Kiyatkin, E. A. (2019) · Temperature · doi:10.1080/23328940.2019.1691896 · Cited by 122
“This drug at low doses induces weak physiological effects and thus appears to be physiologically safe, and it is considered a possible tool to treat post-traumatic stress disorder (PTSD) and some types of depression in humans [215,216].”
Background
Metadata
- Authors
- Doblin, R.
- Venue
- Journal of Psychoactive Drugs
- Publisher
- Informa UK Limited
- Published
- 2002-06-01
- Volume
- 34
- Issue
- 2
- Pages
- 185-194
- ISSN
- 0279-1072 (ISSN-L)
- 2159-9777
- OpenAlex
- W2028998494
- Cited by
- 98
- References
- 5
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA. https://app.cochat.ai/papers/10.1080/02791072.2002.10399952
- The paper
- Doblin, R. (2002). A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2002.10399952
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.